Inhibrx Inc.

Inhibrx Inc.

World Rank (Aug-2026)
8088
Market Cap (Aug-2026)
1.296 Billion USD
Market Cap (Mar-08-2026)
1.006 Billion USD
World Rank (Jan-05-2024)
6,046
Market Cap (Jan-05-2024)
1.809 Billion USD
World Rank (Jul-30-2023)
7,998
World Rank (Jan-07-2022)
8,138
Market Cap (Jan-07-2022)
1.294 Billion USD
World Rank (Jan-01-2021)
7,075
Market Cap (Jan-01-2021)
1.243 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
INBX
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
1 Million USD
Annual Operating Income in USD
-135 Million USD
Annual Net Income in USD
-140 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
146 Million USD
Total Liabilities in USD
138 Million USD
Total Equity in USD
8 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
INHIBRX, INC.
Yahoo
Yahoo @ Nasdaq
Company Profile
Inhibrx is a Clinical Stage Biotechnology company developed a diverse pipeline of therapeutic candidates specifically designed to leverage the power of core sdAb (single-domain antibody) platform and protein engineering expertise. The company annual revenue is 34.1 million USD and 80 employees as on 2020. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share